Ann Pharmacol Pharm | Volume 5, Issue 5 | Research Article | Open Access

Immunotropic Activity of a New Cladribine/Ribavirin-Based Composition

Kalinichenko Elena*, Ponteleeva Irina and Golubeva Marina

Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus, Republic of Belarus 

*Correspondance to: Kalinichenko Elena 

Fulltext PDF


The immunotropic potential of the cladribine and ribavirin combination and its individual components has been studied applying the model of the cell-mediated immune response in F1 (C57Bl/6 × CBA) hybrid mice, as well as the protective potential of the oral drug Leucovir (Leucovir) based on this combination using a model of Experimental Autoimmune Encephalomyelitis (EAE) in guinea pigs.
It has been demonstrated that the combination of cladribine and ribavirin has an immunosuppressive effect on the cell-mediated immune response, which manifests itself as inhibition of antigen-specific T-cells clone formation and inhibition of pro-inflammatory
cytokines production. The combination of cladribine with ribavirin is superior in effectiveness to its individual components. The use of Leucovir makes it possible to successfully control the course of EAE, which reproduces Multiple Sclerosis (MS), both in preventive and therapeutic use. The preventive use of Leucovir significantly reduces the percentage of disease incidence and the
mortality rate, allows delaying the onset of the first EAE signs, and reduces the clinical manifestations of the modeled pathology. The therapeutic use of Leucovir inhibits the progression of neurological impairments, reduces the mortality rate and contributes to a significant increase in the survival time after immunization.
These results suggest that Leucovir, a cladribine- and ribavirin-based oral drug, may have beneficial effects in autoimmune diseases such as MS.


Cladribine; Ribavirin; Leucovir; Multiple sclerosis; Immunomodulation


Elena K, Irina P, Marina G. Immunotropic Activity of a New Cladribine/Ribavirin-Based Composition. Ann Pharmacol Pharm. 2020;5(6):1196..

Subscribe to Our Newsletter